This issue offers data from Q4 of 2022, when South Africa became the fourth country in the world to approve injectable cabotegravir (CAB) for PrEP; the dapivirine vaginal ring (DVR) was approved in a growing number of countries; and oral PrEP use was on the rise, passing the mark of 3.8 million initiations. For the first time, the world has multiple biomedical interventions to offer choice, and it’s essential to develop the programs that bring the fruits of science to the communities facing public health threats, while continuing to invest in developing new options to meet diverse needs.
Px Wire February 2023
Volume 13, Number 1
Advancing HIV Prevention Research in Pregnant and Lactating People (PLP): Think Tank Report & Action Plan
The work of the AVAC/PHASES think tank to advance HIV prevention research with pregnant and lactating people was importantly grounded in a trio of conceptual frameworks: 1. Reproductive Justice, 2. Conceptual shifts articulated in the Pregnancy and HIV/AIDS: Seeking Equitable Study (PHASES) Ethics Guidance and 3. WHO/ IMPAACT framework for accelerated inclusion of pregnant women in pre-licensure clinical trials.
Prevent, Prepare, and Respond: An analysis of global health architecture for pandemic preparedness
2023 will be a pivotal year for global health and the structures that are set up to address it. Decisions being made at the highest levels of government will determine how prepared we are for future pandemics and will reshape how we respond to ongoing ones. AVAC is keen to articulate policy positions on these structural shifts and global policy changes that will determine – among other things – the future of the HIV response.
Picking Up the Pace
PrEP introduction is gaining traction around the world. Check out AVAC’s graphic showing global totals, and the uptick in implementation studies, regulatory approvals, global recommendations and more.
Biomedical HIV Prevention Research in 2022 and Beyond
This report provides a concise update on the full landscape of biomedical interventions: including PrEP products in the market and next-gen products in the pipeline—multipurpose products (MPTs), vaccines and broadly neutralizing antibodies.
Px Wire July-September 2022, Vol. 12, No. 2
PrEP Tracker data, preparing for new products, the HIV prevention pipeline and our prevention playlist. All that and more in the latest issue of Px Wire.
Global Fund Investment Case: Seventh replenishment 2022 executive summary
The Global Fund’s analysis of the economic case for increased investment and commitment to its strategy pandemic preparedness and ending HIV, TB and malaria.
ViiV’s Community Stakeholder Engagement Strategy for Low- and Middle-Income Countries (2022-2024)
ViiV’s 2022-2024 strategy for community stakeholder engagement in low and middle income countries pledges a commitment to Good Participatory Practice Guidelines and more.
Px Wire April-June 2022, Vol. 12, No. 1
Newly relaunched, PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research and development, implementation and advocacy. Download for a quick look at where we are in HIV prevention.
A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP (Summary)
AVAC published Translating Scientific Advance into Public Health Impact: A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP to provide a comprehensive view of all the moving parts and identify specific priority actions and actors responsible for ensuring time is not wasted and opportunity not squandered in introducing injectable cabotegravir for PrEP. ViiV, policy makers, normative agencies, donors, program implementers, researchers, generic manufacturers, civil society, advocates and communities each have critical roles to play in the coming months, and this summary provides an overview of the plan.